Injectable Ketamine Shows Promise in Treatment-Resistant Depression
Twice-weekly subcutaneous ketamine helped alleviate symptoms of treatment-resistant depression, according to the phase III KADS study. Among those who received at least one flexible treatment dose (0.5-0.9 mg/kg), ketamine was more than 12-times better at inducing remission of depression than the benzodiazepine midazolam (remission rate 19.6% vs 2.0%, OR 12.1, 95% CI 2.1-69.2, P=0.005), reported […]